September 17, 2019
1 min read

Topical solution from Aclaris clears warts by day 29 in phase 3 study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Aclaris Therapeutics announced positive results from a phase 3 clinical trial of A-101 45% topical solution, an investigational new drug for the treatment of common warts.

The study, THWART-2, met primary and secondary endpoints, with the topical solution achieving clinically and statistically significant clearance of common warts as early as day 29, according to a press release.

A-101 45% topical solution is a proprietary high-concentration hydrogen peroxide topical treatment being developed as a potential prescription treatment for common warts.

Data from THWART-1, the second phase 3 trial, are expected later this year.

Each trial was randomized, double-blind and vehicle-controlled to evaluate the efficacy and safety of A-101 45% topical solution compared with placebo.

A total of 502 participants with one to six warts at baseline took part in THWART-2 and were randomly assigned to self-administer A-101 45% topical solution or vehicle twice a week for 8 weeks, for a total of 16 treatments.

The trial achieved its primary endpoint in the treatment group: all identified common warts were reported as clear at day 60 (P < .0001), using the Physician Wart Assessment scale.

Additionally, complete clearance was reported in all warts at day 137 (P = .0001) with the treatment solution. Mean per participant percent of treated warts at day 137 and time to complete clearance of all warts were also superior in the A-101 45% topical solution group (P < .0001).

There were no treatment-related serious adverse events in those treated with A-101 45% topical solution, but treatment-related application site adverse events were reported in 53.4%.